| Primary information |
|---|
| OV_ID | OV_2578 |
| Virus Name | Adenovirus |
| Strain | SG600-IL-24+IFN |
| Virus type | DNA |
| Virus family | Adenoviridae |
| Modification in virus genome | Deletion of E1B gene and insertion of IL-24 gene and addition of IN |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | Virus expressing IL-24 gene and IFN gene |
| Source of cell line | ATCC |
| Origin of cell line | Human hepatocellular carcinoma cell line |
| Cell line | HCCLM3 |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | BALB/c nude mice xenograft for HCCLM3 cell line |
| In-vivo virus concentration | 2 × 10⸠pfu
|
| In-vivo toxicity | NA |
| In-vivo result | Significant reduction in tumor volume from the onset of tretament and till the end of 42 days and increase in median survival time |
| Mode of delivery | Intratumoral |
| Pathway induction | Combined therapy increases STAT1, SOCS1 and apoptosis |
| Immunogenic effect | Combined therapy decreases expression of MMP-2, XIAP,OPN and VEGF |
| Clinical trial | NA |
| PMID | 22569271 |